EPISODE · Nov 1, 2021 · 12 MIN
National MS Society Invests $8.7M in Research, Clinical Trial Training
from MS News & Perspectives · host MS News Today
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how National MS Society investments support 29 training fellowships, early career awards, and research projects aligned with its Pathways to Cures Roadmap; and reads “He’s Fallen in the Water!”, a column by John Connor.===================================Treatment for Relapsing MS Progression | MAYZENT® (siponimod)Read about MAYZENT, a once daily pill that can significantly slow down disability progression in people with relapsing MS. See full prescribing & safety info. https://www.mayzent.com/?utm_source=changeinrms&utm_medium=vanityurl&utm_campaign=novartis_mayzent_2020&utm_content=soundcloud ===================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/ =====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/
Embed this episode
NOW PLAYING
National MS Society Invests $8.7M in Research, Clinical Trial Training
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.